Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Bone Marrow Transplantation|February 12, 2008
Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?S Chunduri, L C Dobogai, D Peace, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 28, 1998
Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignanciesM A Rosenthal, D Dennis, L Liebes, et al.
Leukemia|September 3, 2014
FHL2 regulates hematopoietic stem cell functions under stress conditionsY Hou, X Wang, L Li, et al.
Bone Marrow Transplantation|September 19, 2006
Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantationS Chunduri, L C Dobogai, D Peace, et al.
Bone Marrow Transplantation|May 7, 2003
Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovirA Verma, S Devine, M Morrow, et al.
Transplantation|October 3, 1999
Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejectionE S Woodle, D Xu, R A Zivin, et al.
JAMA Network Open|January 3, 2025
Validating a Case Definition for Transgender Adults Using Administrative DataChantal L Rytz, James A King, Nathalie Saad, et al.
Bone Marrow Transplantation|August 28, 2003
Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignanciesK Van Besien, S Devine, A Wickrema, et al.
Bone Marrow Transplantation|October 19, 2001
Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplantS M Devine, R Sanborn, E Jessop, et al.
Bone Marrow Transplantation|June 20, 2003
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignanciesK van Besien, S Devine, A Wickrema, et al.
Pageof 4